Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
All content for ASX BRIEFS is the property of Andrew Musgrave and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
GREAT BOULDER RESOURCES LTD (GBR) - Beyond the Surface: The Hidden Value of Side Well Gold Project
ASX BRIEFS
12 minutes
2 months ago
GREAT BOULDER RESOURCES LTD (GBR) - Beyond the Surface: The Hidden Value of Side Well Gold Project
Send us a text Gold explorers often make big promises, but Great Boulder Resources is quietly delivering real results at its flagship Side Well Gold Project near Meekatharra in Western Australia's gold-rich Murchison region. Managing Director Andrew Paterson shares how they've built a substantial high-grade resource in just four years, with clear pathways to reach one million ounces this year and ambitious plans for 1.5 million ounces in the medium term. The company's approach blends methodi...
ASX BRIEFS
Send us a text A lab surprise turned frontline hope: we sit down with Dr Liz Dallimore, CEO of Argenica Therapeutics, to unpack a peptide drug designed to protect the brain during the chaotic minutes after stroke and other injuries. Built from a chain of arginines, the therapy targets the glutamate‑driven calcium surge that kills neurons, aiming to stabilise tissue while clot dissolvers or thrombectomy restore blood flow. We trace Argenica’s journey from Perth lab benches to a multi‑centre P...
